Wachtwoord vergeten?

Tigenix februari 2017

87 Posts
Pagina: «« 1 2 3 4 5 | Laatste | Omlaag ↓
  1. koopjesjager 1 maart 2017 12:54
    Ik heb op het gebied van Biotech niet zo veel verstand maar het lijkt me een extreem ondergewaard aandeel wat een overname kandidaat is. Ik dacht hier op het Tigenix forum zitten wel wat kenners.

    Hier hun website kan je de clinical trials zien.
  2. koopjesjager 1 maart 2017 13:23
    t’s a fool’s trade. Or rather, we should say, it was.

    After infuriating investors with bankruptcy filings and crumbling valuations for years, stem cell companies have been crushed.

    Many suffered delays, burning through cash with few results.

    StemCells – now Microbot Medical (MBOT) -- fell from a $228 high in 2014 to less than $4 this year.
    International Stem Cell Corporation (ISCO) fell from $56 to $1.10.
    S. Stem Cell (USRM) fell from $80 to less than a penny.
    Vericel Corporation (VCEL) (formerly Aastrom Biosciences) fell from $55 to $2.50, but is beginning to show signs of life at its lows.
    Geron Corporation (GERN), which was responsible for the first human trial to use cells from human embryonic stem cells. Unfortunately, the trial was halted on concerns of purity and predictability of implanted cells, and again after the company report seeing microscopic cysts in the spinal cords of rats.
    It’s been a disaster for investors.

    Some would say it’s not worth the investment. But we beg to differ.

    Just look at recent mergers and acquisitions.

    Thermo Fisher (TMO) just bought MTI-GlobalStem, which provides neural, stem and supporting feeder cells.
    In April 2016, Thermo Fisher acquired Affymetrix, which provides cellular and genetic analysis, tools needed for stem cell research.
    AbbVie (ABBV) bought Stemcentryx for $5.8 billion, helping it add several stem cell cancer therapies to its pipeline.
    Fujifilm (FUJIY) acquired Cellular Dynamics International.
    Smart investors are actually being handed the opportunity of a lifetime at such lows, as stem cell companies look to treat stokes, traumatic brain injury, Alzheimer’s, Parkinson’s, wound healing, osteo- and rheumatoid-arthritis, diabetes and cancer just to name a few…

    It’s exciting… and could be wildly profitable for smart investors.

    Researchers from University College London found that stem cells found in human amniotic fluid could be used to strengthen brittle bones, for example.

    Published research showed 79% fewer bone fractures in mice with brittle bone disease. Out of 324 mice, 168 were treated with 156 in the control group.

    Each control mouse had fractures.

    However, in the experimental group, fractures decreased between 69% and 89%, leading to a 79% decrease in the fracture rates across all test subjects.

    There’s hope is that this can be replicated in humans, and help those that suffer from things such as osteoporosis.

    Brittle bone disease affects up to 50,000 people in the U.S. alone.

    Or, look at regenerative treatments for heart disease.

    In the U.S. and Europe alone, about two million people suffer from heart attacks, which can lead to congestive and chronic heart failure that has no cure other than transplantation. In the U.S., it costs $30 billion to treat heart failure yearly. That’s expected to soar to $70 billion by 2030.

    But cell companies could help there, too.

    In fact, Capricor Therapeutics’ lead candidate CAP-1002 is being tested for safety and effectiveness in impacting heart function, and its ability to decrease scar tissue and promoting growth of heart muscle, which could prevent heart failure.

    At the moment, a number of approved medications are used to treat chronic heart failure, but none change dysfunctional cardiac structure, as Capricor is trying to do.

    Other than heart disease, several other companies will have late-stage stem cell results in the next few quarters, as well or Pediatric Graft vs host disease (GVHD), rheumatoid arthritis, scleroderma, and even severe sepsis.

    Granted, the past hasn’t been kind to stem cells.

    But we’re entering a phase of incredible growth potential again.

    Look at BioTime (BTX), which is now it Phase 1/2a clinical trials in patients with complete cervical spinal cord injury, for example.

    Considering 1.3 million Americans with this injury have no approved therapies or devices to help, this would be a substantial unmet medical need. Worse, the cost of care for an individual averages $3 to $4 million over a person’s lifetime.

    Clearly, there’s demand for such therapy.

    Globally, the market was valued at $37.88 billion in 2013, expected to hit $170.15 billion by 2020 on the heels of increasing research and development and big funding by government for drug discovery and development for unmet medical needs.

    Many of these stem cell companies are still good buys.

    Many are trading at incredible discounts with favorable developments.

    We understand there’s always risk in stem cell companies.

    But for risk-tolerant smart investors, such investments hold a great deal of long-term opportunity. We just recently recommended a trade in Stealth Stock Trader that is showing solid fundamental strength.
    Stay tuned for more.
87 Posts
Pagina: «« 1 2 3 4 5 | Laatste |Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Meer »

Koers 0,000   Verschil 0,00 (0,00%)
Laag 0,000   Volume 0
Hoog 0,000   Gem. Volume 0
1 jan 0001 00:00
label premium


Het laatste advies leest u als IEX Premium-lid

Ontdek Premium
Quotedata: Amsterdam realtime by Euronext, other realtime by Cboe Europe Ltd.   US stocks: by NYSE & Cboe BZX Exchange, 15min delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by Infront. Crypto data by Crypto Compare